-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on BeOne Medicines, Raises Price Target to $446

Benzinga·11/06/2026 16:06:04
Barclays analyst Etzer Darout maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises the price target from $415 to $446.